5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance

Int Immunopharmacol. 2021 Jul:96:107820. doi: 10.1016/j.intimp.2021.107820. Epub 2021 Jun 2.

Abstract

Primary biliary cholangitis (PBC) is a common autoimmune liver disease manifested by the infiltration of CD4+ T cells, and the subsequent targeted injury of biliary epithelial cells (BECs). As important components of CD4 subsets, the Treg/Th17 axis maintains an immunological balance between self-tolerance and inflammation in the liver microenvironment. However, the role and regulatory mechanism of the Treg/Th17 axis in PBC remain unclear. In this study, we examined the Treg/Th17 axis in PBC patients and found that the Treg/Th17 axis was imbalanced in PBC at both the transcriptional and cellular levels, with Treg being a weak candidate, which correlates with the PBC progression. This imbalanced Treg/Th17 axis was likely to be affected by the FoxP3 hypermethylation, which was related to the increase of DNA methyltransferase. Furthermore, the effect of 5-Aza-2-deoxycytidine (DAC)-mediated FoxP3 demethylation on PBC mice was investigated. We verified that DAC significantly suppressed the FoxP3 methylation and rebuilt the Treg/Th17 balance, resulting in the alleviation of liver lesions and inflammation. Taken together, our data indicate that DAC plays a positive role in alleviating the progression of PBC through the inhibition of DNA methylation of FoxP3 to rebuild the balanced Treg/Th17 axis. DAC could be considered as a potential candidate for the development of new anti-inflammation strategies in the treatment of PBC.

Keywords: Forkhead box protein 3; Methylation; Primary biliary cholangitis; Regulatory T cells; T helper 17 cells.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • DNA (Cytosine-5-)-Methyltransferase 1 / genetics
  • DNA Methylation / drug effects
  • DNA-Binding Proteins / genetics
  • Decitabine / pharmacology
  • Decitabine / therapeutic use*
  • Dioxygenases / genetics
  • Female
  • Forkhead Transcription Factors / genetics*
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Liver / metabolism
  • Liver Cirrhosis, Biliary / drug therapy*
  • Liver Cirrhosis, Biliary / genetics
  • Liver Cirrhosis, Biliary / immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • Th17 Cells / drug effects*
  • Th17 Cells / immunology

Substances

  • Anti-Inflammatory Agents
  • DNA-Binding Proteins
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • RORC protein, human
  • Decitabine
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Dioxygenases
  • TET2 protein, human
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNMT1 protein, human